Happiness may protect you from gastrointestinal distress


Monday, 22 June, 2020

Happiness may protect you from gastrointestinal distress

New research from UT Southwestern Medical Center (UTSW) suggests that serotonin, a chemical known for its role in producing feelings of wellbeing and happiness in the brain, can reduce the ability of some intestinal pathogens to cause deadly infections — infections for which few truly effective treatments currently exist.

Although the vast majority of research on serotonin has centred on its effects in the brain, about 90% of this neurotransmitter — a chemical that nerve cells use to communicate with each other — is produced in the gastrointestinal tract. In humans, trillions of bacteria live within this space; most of these gut bacteria are beneficial, but pathogenic bacteria can also colonise the gastrointestinal tract, causing serious and potentially fatal infections.

Because gut bacteria are significantly affected by their environment, UTSW Professor Vanessa Sperandio, doctoral student Aman Kumar, laboratory manager Regan Russell and colleagues wondered whether the serotonin produced in the gut can affect the virulence of pathogenic bacteria that infect the gastrointestinal tract. Their study was published in the journal Cell Host & Microbe.

The researchers worked with Escherichia coli O157, a species of bacteria that causes periodic outbreaks of often deadly foodborne infection. The team grew these pathogenic bacteria in petri dishes in the lab, then exposed them to serotonin. Gene expression tests showed that serotonin significantly reduced the expression of a group of genes that these bacteria use to cause infections. Additional experiments using human cells showed that the bacteria could no longer cause infection-associated lesions on the cells if these bacteria were exposed to serotonin.

Next, the researchers examined how serotonin affected virulence in living hosts. Using mice, they studied how serotonin might change the ability for Citrobacter rodentium — a mouse gut bacterium often used as an analog for E. coli in humans — to infect and sicken their hosts. These mice were genetically modified to either over- or underproduce serotonin in their gastrointestinal tracts. Those that overproduced this neurotransmitter were less likely to become colonised by C. rodentium after being exposed to this bacterium or had relatively minor courses of illness. Treating mice with fluoxetine (sold under the brand name Prozac) to increase serotonin levels prevented them from getting sick from C. rodentium exposure. However, the mice that underproduced serotonin became much sicker after bacterial exposure, often dying from their illness.

Further experiments identified the receptor for serotonin on the surfaces of both E. coli and C. rodentium, a protein known as CpxA. Because many species of gut bacteria also have CpxA, it’s possible that serotonin could have wide-ranging effects on gut bacterial health, Prof Sperandio said.

In the future, the colleagues plan to study the feasibility of manipulating serotonin levels as a way of fighting bacterial infections in the gastrointestinal tract. Currently, few available antibiotics can effectively fight E. coli O157 — some antibiotics actually worsen the consequences of infection, causing the bacteria to release more damaging toxins.

“Treating bacterial infections, especially in the gut, can be very difficult,” Prof Sperandio said. “If we could repurpose Prozac or other drugs in the same class, it could give us a new weapon to fight these challenging infections.”

Image credit: ©stock.adobe.com/au/Ivan Kruk

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

A pre-emptive approach to treating leukaemia relapse

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...

Long COVID abnormalities appear to resolve over time

Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...

RNA-targeted therapy shows promise for childhood dementia

Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd